Shots:

• Mylan’s Remdesivir 100mg/vial Lyophilized Powder for Injection will be launched in India under brand name Desrem in Jul with INR 4-800 which is 80% less to the price of its branded version
• The company will manufacture the product in its injectables facilities in India- which is also inspected by the US FDA for compliance with good manufacturing practices and will be marketed in 127 markets in India
• Remdesivir is an investigational drug targeted for COVID-19 and has demonstrated favorable outcomes in two P-III trials. Additionally- the US FDA granted EUA to treat hospitalized patients with severe COVID-19 based on the two P-III trials results in the US also recommended for compassionate use in EU including Japan- Taiwan- and Singapore

Click here to read full press release/ article | Ref: PRNewswire | Image: PharmaWorld